Don’t Miss Our Presentation and Booth at BioJapan 2023!
Biocytogen’s Asia-Pacific business development team is pleased to present and exhibit at BioJapan 2023, taking place from October 11-13, 2023 in Yokohama, Japan! Dr. Jie…
Read more
Biocytogen Officially Launches RenMice® Series
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen's Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen…
Read more
Sep 2023 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Catalog Number Product 112652 B-h4-1BB mice(C) 111415 B-hADAM15 mice 112939 B-hCD3E/hDLL3 mice 111476 B-hEREG mice 112497 B-hNKG2D mice plus…
Read more
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Beijing, China, September 7, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody…
Read more
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D
Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to…
Read more
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today…
Read more
Meet Us at Our Booth in JCA2023!
Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 82nd annual meeting of the Japanese cancer association, taking place from September 21–23, 2023…
Read more
Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
BEIJING, China--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is…
Read more
Biocytogen Announces Grand Opening of Waltham, MA Facility
State-of-the-Art Facility Signifies Growth of Business in North America and Europe August 16, 2023, Waltham, MA & Beijing, China - Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”),…
Read more
Webinar: Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform
Our webinar “Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen's Renmice-Based Platform" was live at 11:00 AM EDT on Aug 30th, 2023. About the Webinar GPCRs…
Read more